- Policy
- President Moon wearing a mask visited the NMC
- by Kim, Min-Gun Jan 30, 2020 06:33am
- Cheong Wa Dae announced at 10:31 am on the 28th that President Moon Jae-in visited the National Medical Center, which is treating a new type of coronavirus infection, and directly inspected the field response system and ordered a total response posture. Mr. Moon made this report at the spot where he received on-site response system repor
- Policy
- Amendment to cascading drug price revision revealed
- by Kim, Jung-Ju Jan 30, 2020 06:33am
- Finally came the result. The reinstatement of the cascading drug price system was revised and revised to change the generic insurance price according to whether or not it had its own bioequivalence test. As is known, there is a difference in the price of IMDs and generics. Revisions were included to keep the addition in recognition of the eff
- Company
- ‘No Japan’ no effect on drug trade with Japan last year
- by Kim, Jin-Gu Jan 30, 2020 06:33am
- Apparently, imported drug volume from Japan has gone up in last year by 8.3 percent. Experts analyze Koreans boycotting Japanese products took off from the latter half of last year had not affected the pharmaceutical industry. According to import and export statistics disclosed by Korea Customs Service on Jan. 28, Korean drug export volume t
- Policy
- Rafinlar-Meqsel combination done with pricing negotiation
- by Lee, Hye-Kyung Jan 30, 2020 06:33am
- A combination therapy of Rafinlar and Meqsel treating patients with ultra-rare late stage BRAF-mutant lung cancer would be available for reimbursed prescription from next month at earliest. Korea’s National Health Insurance Service (NHIS) has recently announced pricing negotiations on four items&8212;Novartis’ Rafinlar (dabrafenib) 5
- Company
- A Employee, ahead of retirement at Merck, took his own life
- by Eo, Yun-Ho Jan 29, 2020 10:55am
- There was a pity that a salesperson at Merck Bio Pharma, who was about to leave, took his own life. According to the industry, Mr. A, a sales representative from Daejeon Branch of Merck, was found dead. Mr. A was included in the Early Retirement Program (ERP) during the sale of Merck's General Medicine primary care (GM) division, and re
- Policy
- Janssen prepares to close Hyangnam plant, renewing licenses
- by Lee, Tak-Sun Jan 29, 2020 06:27am
- Janssen Korea is to close Hyangnam plant in 2021 and the company is speeding up the process of transferring items manufactured in Hyangnam to other facilities. Apparently some of them would be transferred to other Korean manufacturing companies, whereas some would be manufactured abroad and imported to Korea. As of Jan. 28, Korea’s
- Company
- Breakthrough anticancer Tagrisso makes KRW 29 billion
- by An, Kyung-Jin Jan 29, 2020 06:26am
- AstraZeneca’s new lung cancer treatment Tagrisso has continued to top the prescription drug market. After two years of reimbursement listing, the new drug has generated almost 30 billion won and expanded the overall epidermal growth factor (EGFR) targeted therapy prescription volume. According to pharmaceutical product research firm UBI
- Policy
- Korea-Switzerland promulgated an AMR on GMP
- by Lee, Jeong-Hwan Jan 29, 2020 06:26am
- The AMR (Agreement on Mutual Reliance) on GMP (Good Manufacturing Practice) between Korea and Switzerland was promulgated on the 23rd. It is a follow-up after the MFDS (Ministry of Food and Drug Safety) signed a GMP agreement with the SWISSMEDIC (Swiss Drug Agency) on December 18 last year. The agreement promulgated the mutual recognitio
- Company
- Eylea biosimilar by SCD applies for Phase 3 global IND
- by Lee, Seok-Jun Jan 29, 2020 06:25am
- Samchundang Pharm (SCD) plans to have Phase 3 global clinical trial protocol approved for Eylea’s biosimilar ‘SCD411’ within the first quarter of the year. The protocol approval would be reviewed for 90 days at longest, and green light the company to start the Phase 3 trial by the coming second quarter. The multiregional study is planned
- Policy
- Hanmi’s salt-modifying drug for Galvus was approved
- by Lee, Tak-Sun Jan 29, 2020 06:25am
- A salt alteration drug of Galvus(Vildagliptin) by Hanmi, a DPP-4 inhibitor for diabetes was approved. But one indication in the original drug is excluded. It is understood as a strategy to avoid patent The Ministry of Food and Drug Safety approved the generic product (50mg) for Galvus by Hanmi. Unlike the original galvus, this generic has
